TP53 and acute myeloid leukemia: Based on compelling in vitro and in vivo activity in models of drug-resistant AML with both wild-type TP53 (23) and mutant TP53 (24), including additive activity with decitabine in two animal models of TP53-mutated AML, we sought to evaluate TP-0903’s clinical activity by conducting a phase 1b/2 study evaluating TP-0903 in combination with a 10-day decitabine regimen in patients ages 60 years and older who had newly diagnosed AML with mutant TP53, complex karyotype, or both.